Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016. Dr Simon Kerry, Karus’s CEO, will be presenting on the Oncology track, taking place in the […]

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

First cohort of cancer patients has been dosed with Karus’s lead candidate, KA2237 Potential first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors KA2237 combines an immunotherapeutic response and a direct effect on tumor growth Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active […]

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a lecture at the 15th Annual BIO Investor Forum, San Francisco, California, USA, 18-19 October 2016. Dr Simon Kerry, Karus’s CEO, will be lecturing on oncology as […]